Symptomatic catheter‐related thrombosis (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters
Low‐molecular‐weight heparin (LMWH) probably leads to lower symptomatic catheter‐related thrombosis (up to 3 months) compared with no LMWH (moderate certainty).
1 finding from 1 review
Symptomatic catheter‐related thrombosis measured as asymptomatic catheter‐related thrombosis (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters
It is very uncertain whether low‐molecular‐weight heparin (LMWH) changes symptomatic catheter‐related thrombosis measured as asymptomatic… compared with no LMWH (very low certainty).
1 finding from 1 review
Major bleeding · people with cancer with thrombosis prophylaxis and central venous catheters
It is very uncertain whether low‐molecular‐weight heparin (LMWH) changes major bleeding (up to 3 months) compared with no LMWH (very low certainty).
1 finding from 1 review
Minor bleeding · people with cancer with thrombosis prophylaxis and central venous catheters
Low‐molecular‐weight heparin (LMWH) showed no clear difference in minor bleeding (up to 3 months) compared with no LMWH (low certainty).
1 finding from 1 review
Antibiotic versus heparin only lock/flush solution: catheter‐related infections · people with cancer with thrombosis prophylaxis and central venous catheters
Low‐molecular‐weight heparin (LMWH) showed no clear difference in catheter‐related infection (up to 3 months) compared with no LMWH (low certainty).
1 finding from 1 review
Thrombocytopenia · people with cancer with thrombosis prophylaxis and central venous catheters
Low‐molecular‐weight heparin (LMWH) showed no clear difference in thrombocytopenia (up to 3 months) compared with no LMWH (low certainty).
1 finding from 1 review
Recurrent venous thromboembolism · people > 18 years of age with a diagnosed deep vein thrombosis
It is very uncertain whether low molecular weight heparin and idraparinux changes recurrent venous thromboembolism compared with standard therapy (very low certainty).
1 finding from 1 review
Major bleeding · people > 18 years of age with a diagnosed deep vein thrombosis
The review found no eligible studies for this question.
2 findings from 1 review
All‐cause mortality · people > 18 years of age with a diagnosed deep vein thrombosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All harmful effects · people > 18 years of age with a diagnosed deep vein thrombosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Incidence of hepatic veno‐occlusive disease ( · People undergoing stem cell transplant with malignant diseases
It is very uncertain whether summary of findings: Low molecular weight heparin changes incidence of hepatic veno‐occlusive disease ( compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Overall survival · People undergoing stem cell transplant with malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at 100 days post‐transplant · People undergoing stem cell transplant with malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality attributable to hepatic veno‐occlusive disease ( · People undergoing stem cell transplant with malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · People undergoing stem cell transplant with malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Frequency of adverse events ( · People undergoing stem cell transplant with malignant diseases
It is very uncertain whether summary of findings: Low molecular weight heparin changes frequency of adverse events ( compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Incidence of hepatic veno‐occlusive disease ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
It is very uncertain whether summary of findings: Low molecular weight heparin changes incidence of hepatic veno‐occlusive disease ( compared with prostaglandin E1 (very low certainty).
1 finding from 1 review
Overall survival · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at 100 days post‐transplant · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality attributable to hepatic veno‐occlusive disease ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
It is very uncertain whether summary of findings: Low molecular weight heparin changes mortality attributable to hepatic veno‐occlusive disease ( compared with prostaglandin E1 (very low certainty).
1 finding from 1 review